LAS VEGAS, June 25, 2014 /PRNewswire/ -- Cord Blood America,
Inc. (www.cordblood-america.com) (OTC Bulletin Board: CBAI) ("CBAI"
or the "Company"), announced today the launch of a new service
offering for the isolation and expansion of mesenchymal stem cells
through its wholly owned subsidiary CorCell Companies, Inc.
(CorCell). This service was researched and developed in
CorCell's laboratory and offers expecting parents an additional
stem cell banking option.
Joseph Vicente, President of Cord
Blood America, Inc. commented, "It was just over a year ago when we
announced our launch into the storage of cord tissue, our first
product/service extension in company history from our core
umbilical cord blood offering. In subsequent releases, we
have commented about the success of this launch with approximately
60% of our customers choosing to store both cord blood and a
segment of cord tissue. Today, I am excited to announce this
newest extension of our service offering via the isolation and
expansion of these mesenchymal stem cells."
Dr. Geoffrey O'Neill, Tissue Bank
Director of CBAI added, "Since our entrance into the cord tissue
market, CorCell has added a research and development component in
our laboratory aimed at refining and validating our processes and
services. From this research, we have successfully developed
a process for isolating and expanding cord tissue derived
mesenchymal stem cells, which can be more readily stored and
re-grown as needed. Many clinical trials for degenerative diseases
are currently underway using these cells, and the isolation of
these stem cells provides a readily available resource should they
be needed for future medical treatments. "
"The stem cell banking industry is undergoing significant
change," concluded Mr. Vicente, "Corcell recognizes the importance
of expanding our internal efforts to provide our customers the
latest innovations in stem cell technology, and we envision Corcell
providing an array of stem cell products to support the future
needs of the emerging cellular therapy and regenerative medicine
fields."
About Cord Blood America
Cord Blood America, Inc. is the parent company of CorCell
Companies, Inc. which, along with Cord Blood America, Inc.,
facilitates umbilical cord blood and cord tissue stem cell
processing and storage for expectant parents and their
children. Collected through a safe and non-invasive process,
cord blood stem cells offer a powerful and potentially life-saving
resource for treating a growing number of ailments, including
cancer, leukemia, blood, and immune disorders. To find out more
about Cord Blood America, Inc. and CorCell Companies, Inc., visit
our websites: http://www.cordblood-america.com/ for investor
information and http://www.corcell.com/ for customer
information.
Forward-Looking Statements
Some statements made in this press release are forward-looking
statements, which are made pursuant to the safe harbor provisions
of the Private Securities Litigation Reform Act of 1995. We use
words such as "anticipate," "believe," "expect,'' "future,"
"intend," "plan," and similar expressions to identify
forward-looking statements. These statements including those
related to the growth of the industry, new stem cell treatments,
and Cord Blood America's performance, are only predictions and are
subject to certain risks, uncertainties and assumptions. Additional
risks are identified and described in the Company's public filings
with the Securities and Exchange Commission. Statements made herein
are as of the date of this press release and should not be relied
upon as of any subsequent date. The Company's past performance is
not necessarily indicative of its future performance. The Company
does not undertake, and the Company specifically disclaims any
obligation to update any forward-looking statements to reflect
occurrences, developments, events, or circumstances after the date
of such statement.
Investor
Contact:
|
Cameron
Donahue
|
|
Hayden IR
|
|
(651)
653-1854
|
|
cameron@haydenir.com
|
SOURCE Cord Blood America, Inc.